<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62464">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02292745</url>
  </required_header>
  <id_info>
    <org_study_id>2014- 00235039</org_study_id>
    <secondary_id>2014-002350-39</secondary_id>
    <nct_id>NCT02292745</nct_id>
  </id_info>
  <brief_title>Efficacy and Feasibility of Combining FOLFIRINOX and Stereotactic Radiotherapy for Patients With Irresectable Locally Advanced Pancreatic Cancer.</brief_title>
  <acronym>LAPC-1</acronym>
  <official_title>Efficacy and Feasibility of Combining FOLFIRINOX and Stereotactic Radiotherapy for Patients With Irresectable Locally Advanced Pancreatic Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Foundation for Liver Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Foundation for Liver Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether combining FOLFIRINOX chemotherapy and
      stereotactic radiotherapy in patients with locally advanced pancreatic cancer leads to an
      increase in survival.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>up to 3.5 years after start of therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of toxicity events related to chemotherapy</measure>
    <time_frame>up to 3.5 years after start of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>radiological response rates after chemotherapy and radiotherapy</measure>
    <time_frame>up to 3.5 years after start of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of resections at end of stereotactic radiotherapy</measure>
    <time_frame>up to 3.5 years after start of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to locoregional disease progression</measure>
    <time_frame>up to 3.5 years after start of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to development of distant metastases</measure>
    <time_frame>up to 3.5 years after start of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>predictive value of a set of biological markers for treatment response</measure>
    <time_frame>up to 3.5 years after start of therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Pancreatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Stereotactic radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard of care FOLFIRINOX treatment followed by stereotactic radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>stereotactic radiotherapy</intervention_name>
    <arm_group_label>Stereotactic radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cytological or histologically confirmation of pancreatic cancer.

          -  WHO performance status of 0 or 1

          -  ASA classification I or II

          -  Tumor considered locally advanced after diagnostic work-up including CT-imaging and
             diagnostic laparoscopy.

          -  No evidence of metastatic disease

          -  Largest tumor diameter &lt; 7 cm x 7 cm x 7 cm

          -  Normal renal function (Creatinine â‰¥ 30 ml/min).

          -  Normal liver tests (bilirubin &lt; 1.5 times normal; ALAT/ASAT &lt; 5 times normal)

          -  Normal bone marrow function (WBC &gt; 3.0 x 10e9/L, platelets &gt; 100 x 10e9/L and
             hemoglobin &gt; 5.6 mmol/l)

          -  Age &gt; 18 years and &lt; 75 years

          -  Written informed consent

        Exclusion Criteria:

          -  Prior radiotherapy, chemotherapy or resection (bypass surgery allowed).

          -  Lymph node metastases from primary tumor outside the field of radiation.

          -  Second primary malignancy except in situ carcinoma of the cervix, adequately treated
             non-melanoma skin cancer, or other malignancy treated at least 3 years previously
             without evidence of recurrence.

          -  Pregnancy, breast feeding.

          -  Serious concomitant systemic disorders that would compromise the safety of the
             patient or his/her ability to complete the study, at the discretion of the
             investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. C.H.J. van Eijck, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus MC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Prof. C.H.J. van Eijck, MD, PhD</last_name>
    <email>c.vaneijck@erasmusmc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Prof. C.H.J. van Eijck, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 31, 2017</lastchanged_date>
  <firstreceived_date>July 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>locally advanced pancreatic cancer</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>stereotactic radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
